NASDAQ:PROF Profound Medical (PROF) Stock Price, News & Analysis $6.74 +0.28 (+4.33%) Closing price 04:00 PM EasternExtended Trading$6.80 +0.05 (+0.82%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Profound Medical Stock (NASDAQ:PROF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Profound Medical alerts:Sign Up Key Stats Today's Range$6.07▼$6.8850-Day Range$3.87▼$6.4652-Week Range$3.76▼$9.17Volume188,602 shsAverage Volume86,771 shsMarket Capitalization$203.01 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingHold Company Overview Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches. The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia. The system features a closed-loop control mechanism that precisely adjusts ultrasound energy delivery based on continuous feedback from MR temperature mapping, enabling controlled ablation of prostate tissue while preserving surrounding structures. Founded in 2015, Profound Medical has secured regulatory approvals and clearances in multiple jurisdictions, including CE mark certification for the European market and FDA clearance in the United States. The company has established a network of clinical partners and distributors across North America and Europe, where its technology is being adopted in leading cancer centers and urology clinics. Profound Medical’s leadership comprises professionals with extensive experience in medical device development, clinical operations and regulatory affairs. The company continues to invest in research and development to expand its ultrasound platform for additional therapeutic indications and to support ongoing clinical studies aimed at improving patient outcomes.AI Generated. May Contain Errors. Read More Profound Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScorePROF MarketRank™: Profound Medical scored higher than 27% of companies evaluated by MarketBeat, and ranked 810th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingProfound Medical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialProfound Medical has a consensus price target of $11.00, representing about 61.6% upside from its current price of $6.81.Amount of Analyst CoverageProfound Medical has only been the subject of 1 research reports in the past 90 days.Read more about Profound Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Profound Medical are expected to grow in the coming year, from ($1.12) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Profound Medical is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Profound Medical is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProfound Medical has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Profound Medical's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.30% of the outstanding shares of Profound Medical have been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Profound Medical has recently increased by 0.26%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProfound Medical does not currently pay a dividend.Dividend GrowthProfound Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.30% of the outstanding shares of Profound Medical have been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Profound Medical has recently increased by 0.26%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Profound Medical this week, compared to 2 articles on an average week.Search Interest12 people have searched for PROF on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Profound Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.52% of the stock of Profound Medical is held by insiders.Percentage Held by Institutions47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Profound Medical's insider trading history. Receive PROF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PROF Stock News HeadlinesProfound Medical sees Q3 revenue $5.2M-$5.3M vs. $2.8M last yearOctober 7 at 1:52 PM | msn.comProfound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third QuarterOctober 7 at 7:45 AM | globenewswire.comU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this tiny supplier, the FTC slammed the door. Why?October 8 at 2:00 AM | Behind the Markets (Ad)Profound Medical: Expectations WorsenSeptember 25, 2025 | seekingalpha.comProfound Medical announces launch of TULSA by Texas Prostate, Dallas MedicalSeptember 23, 2025 | msn.comTexas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate TreatmentSeptember 23, 2025 | financialpost.comFTexas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate TreatmentSeptember 23, 2025 | globenewswire.comHow Its Possible to Turn a $7,000 TFSA Into $50,000September 19, 2025 | msn.comSee More Headlines PROF Stock Analysis - Frequently Asked Questions How have PROF shares performed this year? Profound Medical's stock was trading at $7.51 at the start of the year. Since then, PROF shares have decreased by 9.3% and is now trading at $6.8080. How were Profound Medical's earnings last quarter? Profound Medical (NASDAQ:PROF) posted its earnings results on Thursday, August, 14th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.09. The firm earned $2.21 million during the quarter, compared to analyst estimates of $4.75 million. Profound Medical had a negative trailing twelve-month return on equity of 89.74% and a negative net margin of 343.97%. Read the conference call transcript. How do I buy shares of Profound Medical? Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Profound Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Docusign (DOCU). Company Calendar Last Earnings8/14/2025Today10/08/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:PROF CIK1628808 Webwww.profoundmedical.com Phone(647) 476-1350Fax64-7847-3739Employees150Year Founded2008Price Target and Rating Average Price Target for Profound Medical$11.00 High Price Target$11.00 Low Price Target$11.00 Potential Upside/Downside+61.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.82 million Net Margins-343.97% Pretax Margin-343.61% Return on Equity-89.74% Return on Assets-73.06% Debt Debt-to-Equity Ratio0.11 Current Ratio8.53 Quick Ratio7.07 Sales & Book Value Annual Sales$10.68 million Price / Sales19.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book3.39Miscellaneous Outstanding Shares30,120,000Free Float29,663,000Market Cap$205.06 million OptionableOptionable Beta0.66 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:PROF) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Profound Medical Please log in to your account or sign up in order to add this asset to your watchlist. Share Profound Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.